The impact of biologics on health-related quality of life in patients with inflammatory bowel disease

References

• HelzerJEChammasSNorlandCCStillingsWAAlpersDHA study of the association between Crohn’s disease and psychiatric illnessGastroenterology1984863243306690360
   PubMed Web of Science ®Google Scholar
• FullwoodADrossmanDAThe relationship of psychiatric illness with gastrointestinal diseaseAnnu Rev Med1995464834967598481
   PubMed Web of Science ®Google Scholar
• LevensteinSLiZAlmerSCross-cultural variation in disease-related concerns among patients with inflammatory bowel diseaseAm J Gastroenterol2001961822183011419836
   PubMed Web of Science ®Google Scholar
• JankeKHKlumpBGregorMMeisnerCHaeuserWDeterminants of life satisfaction in inflammatory bowel diseaseInflamm Bowel Dis20051127228615735434
   PubMed Web of Science ®Google Scholar
• BernklevTJahnsenJAadlandEGroup ISHealth-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosisScand J Gastroenterol20043936537315125469
   PubMed Web of Science ®Google Scholar
• MussellMBockerUNagelNSingerMVPredictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel diseaseEur J Gastroenterol Hepatol2004161273128015618832
   PubMed Web of Science ®Google Scholar
• van der Zaag-LoonenHJGrootenhuisMALastBFDerkxHHCoping strategies and quality of life of adolescents with inflammatory bowel diseaseQual Life Res2004131011101915233514
   PubMed Web of Science ®Google Scholar
• MinderhoudIMOldenburgBvan DamPSvan Berge HenegouwenGPHigh prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiencyAm J Gastroenterol2003981088109312809832
   PubMed Web of Science ®Google Scholar
• CasellasFLopez-VivancosJVergaraMMalageladaJImpact of inflammatory bowel disease on health-related quality of lifeDig Dis19991720821810754360
   PubMed Web of Science ®Google Scholar
• IrvineEJQuality of life issues in patients with inflammatory bowel diseaseAm J Gastroenterol19979218S24S9395348
   PubMed Web of Science ®Google Scholar
• SingletonJWLawDHKelleyMLJrMekhjianHSSturdevantRANational Cooperative Crohn’s Disease Study: adverse reactions to study drugsGastroenterology19797787088238177
   PubMed Web of Science ®Google Scholar
• PresentDHMeltzerSJKrumholzMPWolkeAKorelitzBI6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicityAnn Intern Med19891116416492802419
   PubMed Web of Science ®Google Scholar
• EganLJSandbornWJMethotrexate for inflammatory bowel disease: pharmacology and preliminary resultsMayo Clin Proc19967169808538238
   PubMed Web of Science ®Google Scholar
• DrossmanDALesermanJLiZMMitchellCMZagamiEAPatrickDLThe rating form of IBD patient concerns: a new measure of health statusPsychosom Med1991537017121758953
   PubMed Web of Science ®Google Scholar
• CasellasFLopez-VivancosJCasadoAMalageladaJRFactors affecting health related quality of life of patients with inflammatory bowel diseaseQual Life Res20021177578112482161
   PubMed Web of Science ®Google Scholar
• PizziLTWestonCMGoldfarbNIImpact of chronic conditions on quality of life in patients with inflammatory bowel diseaseInflamm Bowel Dis200612475216374258
   PubMed Web of Science ®Google Scholar
• SaibeniSCortinovisIBerettaLGender and disease activity influence health-related quality of life in inflammatory bowel diseasesHepatogastroenterology20055250951515816468
   PubMedGoogle Scholar
• CasellasFLopez-VivancosJBadiaXVilasecaJMalageladaJRInfluence of inflammatory bowel disease on different dimensions of quality of lifeEur J Gastroenterol Hepatol20011356757211396538
   PubMed Web of Science ®Google Scholar
• CasellasFArenasJIBaudetJSImpairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter studyInflamm Bowel Dis20051148849615867589
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJBalaMResponse and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisInflamm Bowel Dis2007131135114017476675
   PubMed Web of Science ®Google Scholar
• CasellasFLopez-VivancosJBadiaXVilasecaJMalageladaJRImpact of surgery for Crohn’s disease on health-related quality of lifeAm J Gastroenterol20009517718210638579
   PubMed Web of Science ®Google Scholar
• LichtensteinGRYanSBalaMHanauerSRemission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeriesAm J Gastroenterol200499919614687148
   PubMed Web of Science ®Google Scholar
• CosnesJCattanSBlainALong-term evolution of disease behavior of Crohn’s diseaseInflamm Bowel Dis2002824425012131607
   PubMed Web of Science ®Google Scholar
• RobinsonMHanauerSHoopRZbrozekAWilkinsonCMesalamine capsules enhance the quality of life for patients with ulcerative colitisAliment Pharmacol Ther1994827348186343
   PubMed Web of Science ®Google Scholar
• SingletonJWHanauerSBGitnickGLMesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study GroupGastroenterology1993104129313018482443
   PubMed Web of Science ®Google Scholar
• SutherlandLRMartinFBaileyRJA randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study GroupGastroenterology1997112106910779097988
   PubMed Web of Science ®Google Scholar
• SingletonJWHanauerSRobinsonMQuality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn’s diseaseDig Dis Sci1995409319357729281
   PubMed Web of Science ®Google Scholar
• FeaganBGMcDonaldJWRochonJLow-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial InvestigatorsN Engl J Med1994330184618518196727
   PubMed Web of Science ®Google Scholar
• GreenbergGRFeaganBGMartinFOral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study GroupN Engl J Med19943318368418078529
   PubMed Web of Science ®Google Scholar
• Bar-MeirSChowersYLavyABudesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study GroupGastroenterology19981158358409753485
   PubMed Web of Science ®Google Scholar
• FeaganBGRochonJFedorakRNMethotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group InvestigatorsN Engl J Med19953322922977816064
   PubMed Web of Science ®Google Scholar
• BernklevTJahnsenJSchulzTCourse of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosisEur J Gastroenterol Hepatol2005171037104516148548
   PubMed Web of Science ®Google Scholar
• JuanJEstiarteRColomeEBurden of illness of Crohn’s disease in SpainDig Liver Dis20033585386114703880
   PubMedGoogle Scholar
• AgnholtJ[Biological therapy as treatment of inflammatory bowel diseases]Ugeskr Laeger20081702152215618565302
   PubMedGoogle Scholar
• BoonenADagneliePCFeleusAThe impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control studyInflamm Bowel Dis2002838238912454613
   PubMed Web of Science ®Google Scholar
• BassiADoddSWilliamsonPBodgerKCost of illness of inflammatory bowel disease in the UK: a single centre retrospective studyGut2004531471147815361497
   PubMed Web of Science ®Google Scholar
• BodgerKCost of illness of Crohn’s diseasePharmacoeconomics20022063965212162753
   PubMed Web of Science ®Google Scholar
• HayJWHayARInflammatory bowel disease: costs-of-illnessJ Clin Gastroenterol1992143093171607607
   PubMed Web of Science ®Google Scholar
• Abakar-MahamatAFilippiJPradierCDozolAHebuterneXIncidence of inflammatory bowel disease in Corsica from 2002 to 2003Gastroenterol Clin Biol2007311098110318176365
   PubMedGoogle Scholar
• Gower-RousseauCSalomezJLDupasJLIncidence of inflammatory bowel disease in northern France (1988–1990)Gut199435143314387959201
   PubMed Web of Science ®Google Scholar
• LatourPLouisEBelaicheJIncidence of inflammatory bowel disease in the area of Liege: a 3 years prospective study (1993–1996)Acta Gastroenterol Belg1998614104139923091
   PubMed Web of Science ®Google Scholar
• ShivanandaSLennard-JonesJLoganRIncidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)Gut1996396906979014768
   PubMed Web of Science ®Google Scholar
• IrvineEJFeaganBRochonJQuality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study GroupGastroenterology19941062872968299896
   PubMed Web of Science ®Google Scholar
• WareJJrKosinskiMKellerSDA 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validityMed Care1996342202338628042
   PubMed Web of Science ®Google Scholar
• WareJEJrKosinskiMBaylissMSMcHorneyCARogersWHRaczekAComparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes StudyMed Care199533AS264AS2797723455
   PubMed Web of Science ®Google Scholar
• WareJEJrKosinskiMGandekBThe factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life AssessmentJ Clin Epidemiol199851115911659817133
   PubMed Web of Science ®Google Scholar
• PallisAGVlachonikolisIGMouzasIAAssessing health-related quality of life in patients with inflammatory bowel disease, in Crete, GreeceBMC Gastroenterol20022111866863
   PubMedGoogle Scholar
• IrvineEJDevelopment and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel diseaseJ Pediatr Gastroenterol Nutr199928S23S2710204520
   PubMed Web of Science ®Google Scholar
• WareJSnowKKosinskiMGandekBThe SF-36 health survey manual and interpretation guideBostonThe Health Institute, New England Medical Center1993
   Google Scholar
• WareJEKosinskiMInterpreting SF-36 summary health measures: a responseQual Life Res200110405413 discussion 415–42011763203
   PubMed Web of Science ®Google Scholar
• SamsaGEdelmanDRothmanMLWilliamsGRLipscombJMatcharDDetermining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark IIPharmacoeconomics19991514115510351188
   PubMed Web of Science ®Google Scholar
• KosinskiMZhaoSZDedhiyaSOsterhausJTWareJEJrDetermining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritisArthritis Rheum2000431478148710902749
   PubMed Web of Science ®Google Scholar
• LichtensteinGRBalaMHanCDeWoodyKSchaibleTInfliximab improves quality of life in patients with Crohn’s diseaseInflamm Bowel Dis2002823724312131606
   PubMed Web of Science ®Google Scholar
• FeaganBGReinischWRutgeertsPThe effects of infliximab therapy on health-related quality of life in ulcerative colitis patientsAm J Gastroenterol200710279480217324131
   PubMed Web of Science ®Google Scholar
• FeaganBGYanSBalaMBaoWLichtensteinGRThe effects of infliximab maintenance therapy on health-related quality of lifeAm J Gastroenterol2003982232223814572573
   PubMed Web of Science ®Google Scholar
• LoftusEVFeaganBGColombelJFEffects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trialAm J Gastroenterol20081033132314118853973
   PubMed Web of Science ®Google Scholar
• RutgeertsPSchreiberSFeaganBKeiningerDLO’NeilLFedorakRNGroup CDPCsDSCertolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn’s diseaseInt J Colorectal Dis20082328929618071721
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med200735722823817634458
   PubMed Web of Science ®Google Scholar
• SchreiberSKhaliq-KareemiMLawranceICMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med200735723925017634459
   PubMed Web of Science ®Google Scholar
• SchreiberSRutgeertsPFedorakRNA randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s diseaseGastroenterology200512980781816143120
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJHassSNieckoTWhiteJHealth-related quality of life during natalizumab maintenance therapy for Crohn’s diseaseAm J Gastroenterol20071022737274618042106
   PubMed Web of Science ®Google Scholar
• SandsBEKozarekRSpainhourJSafety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximabInflamm Bowel Dis20071321117206633
   PubMed Web of Science ®Google Scholar
• FeaganBGMaintenance therapy for inflammatory bowel diseaseAm J Gastroenterol200398S6S1714697913
   PubMed Web of Science ®Google Scholar
• CreedFFernandesLGuthrieENorth of England IBSRGThe cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndromeGastroenterology200312430331712557136
   PubMed Web of Science ®Google Scholar
• DeterHCKellerWvon WietersheimJJantschekGDuchmannRZeitzMGerman Study Group on Psychosocial Intervention in Crohn’s DPsychological treatment may reduce the need for healthcare in patients with Crohn’s diseaseInflamm Bowel Dis20071374575217230495
   PubMed Web of Science ®Google Scholar
• FeaganBGBalaMYanSOlsonAHanauerSUnemployment and disability in patients with moderately to severely active Crohn’s diseaseJ Clin Gastroenterol20053939039515815207
   PubMed Web of Science ®Google Scholar